Profound Medical (TSE:PRN) Trading Down 2.8% – Should You Sell?

Profound Medical Corp. (TSE:PRN) shares fell 2.8% during trading on Tuesday . The company traded as low as C$9.09 and last traded at C$9.24. 5,931 shares were traded during trading, a decline of 67% from the average session volume of 18,186 shares. The stock had previously closed at C$9.51.

Profound Medical Price Performance

The stock’s 50-day moving average price is C$8.84 and its 200 day moving average price is C$9.40. The firm has a market cap of C$347.03 million, a price-to-earnings ratio of -7.70 and a beta of 1.00. The company has a quick ratio of 14.98, a current ratio of 6.56 and a debt-to-equity ratio of 12.56.

Profound Medical (TSE:PRN) last announced its quarterly earnings data on Thursday, May 7th. The company reported C$0.26 EPS for the quarter. The business had revenue of C$7.42 million during the quarter. Profound Medical had a negative net margin of 199.38% and a negative return on equity of 75.55%. Equities research analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Insiders Place Their Bets

In other Profound Medical news, Director Dr. Arun Menawat bought 20,000 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average price of C$6.96 per share, with a total value of C$139,200.00. Following the completion of the purchase, the director directly owned 658,660 shares in the company, valued at C$4,584,273.60. The trade was a 3.13% increase in their position. 8.62% of the stock is currently owned by insiders.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.